- Home
- EMBC vs QURE Comparison
EMBC vs QURE Comparison
Compare EMBC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMBC
- QURE
- Stock Information
- Founded
- EMBC 1924
- QURE 1998
- Country
- EMBC United States
- QURE Netherlands
- Employees
- EMBC N/A
- QURE N/A
- Industry
- EMBC Medical/Dental Instruments
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- EMBC Health Care
- QURE Health Care
- Exchange
- EMBC Nasdaq
- QURE Nasdaq
- Market Cap
- EMBC 788.4M
- QURE 866.3M
- IPO Year
- EMBC N/A
- QURE 2007
- Fundamental
- Price
- EMBC $15.11
- QURE $16.95
- Analyst Decision
- EMBC Buy
- QURE Strong Buy
- Analyst Count
- EMBC 2
- QURE 11
- Target Price
- EMBC $18.50
- QURE $39.91
- AVG Volume (30 Days)
- EMBC 507.0K
- QURE 966.4K
- Earning Date
- EMBC 08-08-2025
- QURE 11-04-2025
- Dividend Yield
- EMBC 3.90%
- QURE N/A
- EPS Growth
- EMBC 18.26
- QURE N/A
- EPS
- EMBC 1.42
- QURE N/A
- Revenue
- EMBC $1,102,500,000.00
- QURE $14,337,000.00
- Revenue This Year
- EMBC N/A
- QURE N/A
- Revenue Next Year
- EMBC N/A
- QURE $301.10
- P/E Ratio
- EMBC $10.82
- QURE N/A
- Revenue Growth
- EMBC N/A
- QURE N/A
- 52 Week Low
- EMBC $9.20
- QURE $4.45
- 52 Week High
- EMBC $21.48
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- EMBC 66.06
- QURE 59.46
- Support Level
- EMBC $14.51
- QURE $16.69
- Resistance Level
- EMBC $15.44
- QURE $17.76
- Average True Range (ATR)
- EMBC 0.50
- QURE 0.77
- MACD
- EMBC -0.04
- QURE 0.01
- Stochastic Oscillator
- EMBC 79.59
- QURE 58.62
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.